{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,28]],"date-time":"2026-03-28T19:33:57Z","timestamp":1774726437924,"version":"3.50.1"},"reference-count":98,"publisher":"Oxford University Press (OUP)","issue":"1","license":[{"start":{"date-parts":[[2022,9,30]],"date-time":"2022-09-30T00:00:00Z","timestamp":1664496000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2023,1,13]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Background<\/jats:title>\n                  <jats:p>Histone deacetylase inhibitors (HDACi) including valproic acid (VPA) have the potential to improve radiotherapy (RT) efficacy and reduce treatment adverse events (AE) via epigenetic modification and radio-sensitization of neoplastic cells. This systematic review and meta-analysis aimed to assess the efficacy and AE associated with HDACi used as radio-sensitizers in adult solid organ malignancy patients.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>A systematic review utilized electronic searches of MEDLINE(Ovid), Embase(Ovid), The Cochrane Library, and the International Clinical Trials Registry Platform to identify studies examining the efficacy and AEs associated with HDACi treatment in solid organ malignancy patients undergoing RT. Meta-analysis was performed with overall survival (OS) reported as hazard ratios (HR) as the primary outcome measure. OS reported as median survival difference, and AEs were secondary outcome measures.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>Ten studies reporting on the efficacy and\/or AEs of HDACi in RT-treated solid organ malignancy patients met inclusion criteria. All included studies focused on HDACi valproic acid (VPA) in high-grade glioma patients, of which 9 studies (n\u2005=\u20056138) evaluated OS and 5 studies (n\u2005=\u20051055) examined AEs. The addition of VPA to RT treatment protocols resulted in improved OS (HR\u2005=\u20050.80, 95% CI 0.67\u20130.96). No studies focusing on non-glioma solid organ malignancy patients, or non-VPA HDACi met the inclusion criteria for this review.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusions<\/jats:title>\n                  <jats:p>This review suggests that glioma patients undergoing RT may experience prolonged survival due to HDACi VPA administration. Further randomized controlled trials are required to validate these findings. Additionally, more research into the use of HDACi radio-adjuvant treatment in non-glioma solid organ malignancies is warranted.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1093\/nop\/npac078","type":"journal-article","created":{"date-parts":[[2022,9,30]],"date-time":"2022-09-30T20:15:53Z","timestamp":1664568953000},"page":"13-23","source":"Crossref","is-referenced-by-count":7,"title":["Valproic acid as a radio-sensitizer in glioma: A systematic review and meta-analysis"],"prefix":"10.1093","volume":"10","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1567-1053","authenticated-orcid":false,"given":"Jessica K","family":"Sullivan","sequence":"first","affiliation":[{"name":"School of Medicine, Flinders University , South Australia , Australia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Paul P","family":"Fahey","sequence":"additional","affiliation":[{"name":"School of Health Sciences, Western Sydney University , New South Wales , Australia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kinglsey E","family":"Agho","sequence":"additional","affiliation":[{"name":"School of Health Sciences, Western Sydney University , New South Wales , Australia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Simon P","family":"Hurley","sequence":"additional","affiliation":[{"name":"School of Medicine, Flinders University , South Australia , Australia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5746-0241","authenticated-orcid":false,"given":"Zhihui","family":"Feng","sequence":"additional","affiliation":[{"name":"School of Public Health, Cheeloo College of Medicine, Shandong University , Jinan , China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Richard O","family":"Day","sequence":"additional","affiliation":[{"name":"St Vincent\u2019s Clinical Campus, University of New South Wales , New South Wales , Australia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"David","family":"Lim","sequence":"additional","affiliation":[{"name":"School of Medicine, Flinders University , South Australia , Australia"},{"name":"School of Health Sciences, Western Sydney University , New South Wales , Australia"},{"name":"Centre for Remote Health: A JBI Affiliated Centre , Alice Springs , Australia"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2022,9,30]]},"reference":[{"key":"2023011310284782100_CIT0001","author":"World Health Organisation International Agency for Research on Cancer","year":"2020"},{"issue":"30","key":"2023011310284782100_CIT0002","doi-asserted-by":"crossref","first-page":"2457","DOI":"10.2217\/fon-2020-0385","article-title":"The combination of histone deacetylase inhibitors and radiotherapy: a promising novel approach for cancer treatment","volume":"16","author":"Shirbhate","year":"2020","journal-title":"Future Oncol."},{"issue":"10","key":"2023011310284782100_CIT0003","doi-asserted-by":"crossref","first-page":"1153","DOI":"10.1016\/S1470-2045(15)00222-3","article-title":"Expanding global access to radiotherapy","volume":"16","author":"Atun","year":"2015","journal-title":"Lancet Oncol."},{"issue":"1113","key":"2023011310284782100_CIT0004","doi-asserted-by":"crossref","first-page":"578011","DOI":"10.3389\/fgene.2020.578011","article-title":"Synergistic enhancement of cancer therapy using HDAC inhibitors: opportunity for clinical trials","volume":"11","author":"Hontecillas-Prieto","year":"2020","journal-title":"Front Genet."},{"issue":"28","key":"2023011310284782100_CIT0005","doi-asserted-by":"crossref","first-page":"3885","DOI":"10.1038\/sj.onc.1209417","article-title":"Modulation of cellular radiation responses by histone deacetylase inhibitors","volume":"25","author":"Karagiannis","year":"2006","journal-title":"Oncogene."},{"key":"2023011310284782100_CIT0006","doi-asserted-by":"crossref","first-page":"113825","DOI":"10.1016\/j.ejmech.2021.113825","article-title":"Combining histone deacetylase inhibitors (HDACis) with other therapies for cancer therapy","volume":"226","author":"Zhou","year":"2021","journal-title":"Eur J Med Chem."},{"issue":"4","key":"2023011310284782100_CIT0007","doi-asserted-by":"crossref","first-page":"560","DOI":"10.1177\/1756283X16644247","article-title":"Epigenetic therapy in gastrointestinal cancer: the right combination","volume":"9","author":"Abdelfatah","year":"2016","journal-title":"Therap Adv Gastroenterol."},{"issue":"3","key":"2023011310284782100_CIT0008","doi-asserted-by":"crossref","first-page":"904","DOI":"10.1016\/j.ijrobp.2008.10.032","article-title":"A Systematic assessment of radiation dose enhancement by 5-aza-2\u2032-deoxycytidine and histone deacetylase inhibitors in head-and-neck squamous cell carcinoma","volume":"73","author":"De Schutter","year":"2009","journal-title":"Int J Radiat Oncol Biol Phys."},{"key":"2023011310284782100_CIT0009","doi-asserted-by":"crossref","first-page":"503422","DOI":"10.1016\/j.mrgentox.2021.503422","article-title":"Histone deacetylase inhibitor 2-hexyl-4-pentynoic acid enhances hydroxyurea therapeutic effect in triple-negative breast cancer cells","volume":"873","author":"Ding","year":"2022","journal-title":"Mutat Res Genet Toxicol Environ Mutagen."},{"key":"2023011310284782100_CIT0010","doi-asserted-by":"crossref","first-page":"e839","DOI":"10.1016\/j.wneu.2021.04.134","article-title":"Current landscape and future prospects of radiation sensitizers for malignant brain tumors: a systematic review","volume":"151","author":"Beg","year":"2021","journal-title":"World Neurosurg."},{"issue":"4","key":"2023011310284782100_CIT0011","doi-asserted-by":"crossref","first-page":"376","DOI":"10.1016\/S1474-4422(18)30468-X","article-title":"Global, regional, and national burden of brain and other CNS cancer, 1990\u20132016: a systematic analysis for the Global Burden of Disease Study 2016","volume":"18","author":"Patel","year":"2019","journal-title":"Lancet Neurol."},{"issue":"1","key":"2023011310284782100_CIT0012","first-page":"3","article-title":"Glioblastoma multiforme: a review of its epidemiology and pathogenesis through clinical presentation and treatment","volume":"18","author":"Hanif","year":"2017","journal-title":"Asian Pac J Cancer Prev."},{"issue":"5","key":"2023011310284782100_CIT0013","first-page":"e8195","article-title":"Rising incidence of glioblastoma multiforme in a well-defined population","volume":"12","author":"Grech","year":"2020","journal-title":"Cureus."},{"issue":"3","key":"2023011310284782100_CIT0014","doi-asserted-by":"crossref","first-page":"370","DOI":"10.1093\/neuonc\/noy164","article-title":"Glioblastoma survival is improving despite increasing incidence rates: a nationwide study between 2000 and 2013 in Finland","volume":"21","author":"Korja","year":"2019","journal-title":"Neuro Oncol."},{"key":"2023011310284782100_CIT0015","first-page":"7910754","article-title":"Brain tumours: rise in glioblastoma multiforme incidence in England 1995-2015 suggests an adverse environmental or lifestyle factor","volume":"2018","author":"Philips","year":"2018","journal-title":"J Environ Public Health."},{"issue":"1","key":"2023011310284782100_CIT0016","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1007\/s11060-011-0738-7","article-title":"Improved survival time trends for glioblastoma using the SEER 17 population-based registries","volume":"107","author":"Koshy","year":"2012","journal-title":"J Neurooncol."},{"key":"2023011310284782100_CIT0017","doi-asserted-by":"crossref","first-page":"e355","DOI":"10.1016\/j.wneu.2022.02.001","article-title":"Global research trends in radiotherapy for gliomas: a systematic bibliometric analysis","volume":"161","author":"Zhang","year":"2022","journal-title":"World Neurosurg."},{"issue":"9","key":"2023011310284782100_CIT0018","doi-asserted-by":"crossref","first-page":"2378","DOI":"10.11124\/JBIES-21-00466","article-title":"Histone deacetylase inhibitor use as a radiosensitizer in solid organ malignancies: a systematic review protocol","volume":"20","author":"Sullivan","year":"2022","journal-title":"JBI Evid Synth."},{"key":"2023011310284782100_CIT0019","volume-title":"World Health Organization Model List of Essential Medicines \u2013 22nd","author":"WHO\/MHP\/HPS\/EML.","year":"2021"},{"key":"2023011310284782100_CIT0020","year":"2021"},{"issue":"5","key":"2023011310284782100_CIT0021","doi-asserted-by":"crossref","first-page":"226","DOI":"10.5694\/mja17.00951","article-title":"The management of epilepsy in children and adults","volume":"208","author":"Perucca","year":"2018","journal-title":"Med J Aust."},{"key":"2023011310284782100_CIT0022","author":"European Medicines Agency - Valproate and related substances","year":"2018"},{"issue":"3","key":"2023011310284782100_CIT0023","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1007\/s11060-004-2338-2","article-title":"P450 enzyme inducing and non-enzyme inducing antiepileptics in glioblastoma patients treated with standard chemotherapy","volume":"72","author":"Oberndorfer","year":"2005","journal-title":"J Neuro Oncol."},{"issue":"2","key":"2023011310284782100_CIT0024","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1007\/s11060-014-1713-x","article-title":"The effect of valproic acid in combination with irradiation and temozolomide on primary human glioblastoma cells","volume":"122","author":"Hosein","year":"2015","journal-title":"J Neurooncol."},{"issue":"13","key":"2023011310284782100_CIT0025","doi-asserted-by":"crossref","first-page":"3411","DOI":"10.1093\/emboj\/cdg315","article-title":"The histone deacetylase inhibitor valproic acid selectively induces proteasomal degradation of HDAC2","volume":"22","author":"Kr\u00e4mer","year":"2003","journal-title":"EMBO J."},{"issue":"5","key":"2023011310284782100_CIT0026","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1016\/S1474-4422(07)70103-5","article-title":"Epilepsy in patients with brain tumours: epidemiology, mechanisms, and management","volume":"6","author":"van Breemen","year":"2007","journal-title":"Lancet Neurol."},{"issue":"1","key":"2023011310284782100_CIT0027","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1111\/1744-1633.12102","article-title":"Risk factors for seizures and antiepileptic drug-associated adverse effects in high-grade glioma patients: a multicentre, retrospective study in Hong Kong","volume":"19","author":"Woo","year":"2015","journal-title":"Surg Pract."},{"issue":"9","key":"2023011310284782100_CIT0028","doi-asserted-by":"crossref","first-page":"1519","DOI":"10.1007\/s00415-009-5156-9","article-title":"Efficacy of antiepileptic drugs in patients with gliomas and seizures","volume":"256","author":"van Breemen","year":"2009","journal-title":"J Neurol."},{"issue":"9","key":"2023011310284782100_CIT0029","first-page":"693","article-title":"2-Hexyl-4-Pentylenic Acid (HPTA) stimulates the radiotherapy-induced abscopal effect on distal tumor through polarization of tumor-associated macrophages","volume":"34","author":"Duan","year":"2021","journal-title":"Biomed Environ Sci."},{"issue":"6","key":"2023011310284782100_CIT0030","first-page":"955","article-title":"Valproic acid triggers radiation-induced abscopal effect by modulating the unirradiated tumor immune microenvironment in a rat model of breast cancer","volume":"62","author":"Jin","year":"2021","journal-title":"J Radiat Res."},{"key":"2023011310284782100_CIT0031","doi-asserted-by":"crossref","first-page":"102940","DOI":"10.1016\/j.dnarep.2020.102940","article-title":"2-hexyl-4-pentynoic acid, a potential therapeutic for breast carcinoma by influencing RPA2 hyperphosphorylation-mediated DNA repair","volume":"95","author":"Ding","year":"2020","journal-title":"DNA Repair (Amst)."},{"key":"2023011310284782100_CIT0032","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1016\/j.clineuro.2018.09.019","article-title":"The survival effect of valproic acid in glioblastoma and its current trend: a systematic review and meta-analysis","volume":"174","author":"Lu","year":"2018","journal-title":"Clin Neurol Neurosurg."},{"issue":"10","key":"2023011310284782100_CIT0033","doi-asserted-by":"crossref","first-page":"830","DOI":"10.1016\/j.seizure.2014.06.015","article-title":"Survival analysis for valproic acid use in adult glioblastoma multiforme: a meta-analysis of individual patient data and a systematic review","volume":"23","author":"Yuan","year":"2014","journal-title":"Seizure."},{"key":"2023011310284782100_CIT0034","article-title":"Chapter 3: Systematic reviews of effectiveness..","volume-title":"JBI Manual for Evidence Synthesis.","author":"Tufanaru","year":"2020"},{"issue":"37","key":"2023011310284782100_CIT0035","doi-asserted-by":"crossref","first-page":"62742","DOI":"10.18632\/oncotarget.18409","article-title":"Improving radiotherapy in cancer treatment: promises and challenges","volume":"8","author":"Chen","year":"2017","journal-title":"Oncotarget."},{"issue":"3","key":"2023011310284782100_CIT0036","doi-asserted-by":"crossref","first-page":"477","DOI":"10.3390\/biom10030477","article-title":"The role of nicotinamide in cancer chemoprevention and therapy","volume":"10","author":"Nikas","year":"2020","journal-title":"Biomolecules."},{"key":"2023011310284782100_CIT0037","article-title":"Chapter 7: systematic reviews of etiology and risk","volume-title":"JBI Manual for Evidence Synthesis","author":"Moola","year":"2020"},{"key":"2023011310284782100_CIT0038","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1002\/9780470743386.ch25","article-title":"Chapter 25: multiple comparisons within a study","volume-title":"Introduction to meta-analysis","author":"Borenstein","year":"2009"},{"key":"2023011310284782100_CIT0039","author":"RStudio: Integrated development invironment for R","year":"2021"},{"key":"2023011310284782100_CIT0040","doi-asserted-by":"crossref","first-page":"n71","DOI":"10.1136\/bmj.n71","article-title":"The PRISMA 2020 statement: an updated guideline for reporting systematic reviews","volume":"372","author":"Page","year":"2021","journal-title":"BMJ."},{"issue":"12","key":"2023011310284782100_CIT0041","doi-asserted-by":"crossref","first-page":"1156","DOI":"10.1212\/WNL.0b013e31822f02e1","article-title":"Prolonged survival with valproic acid use in the EORTC\/NCIC temozolomide trial for glioblastoma","volume":"77","author":"Weller","year":"2011","journal-title":"Neurology."},{"issue":"3","key":"2023011310284782100_CIT0042","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1007\/s00228-016-2167-1","article-title":"Valproic acid reduces hair loss and improves survival in patients receiving temozolomide-based radiation therapy for high-grade glioma","volume":"73","author":"Watanabe","year":"2017","journal-title":"Eur J Clin Pharmacol."},{"issue":"3","key":"2023011310284782100_CIT0043","doi-asserted-by":"crossref","first-page":"504","DOI":"10.1016\/j.ijrobp.2013.02.012","article-title":"Valproic acid use during radiation therapy for glioblastoma associated with improved survival","volume":"86","author":"Barker","year":"2013","journal-title":"Int J Radiat Oncol Biol Phys."},{"issue":"7","key":"2023011310284782100_CIT0044","doi-asserted-by":"crossref","first-page":"731","DOI":"10.1200\/JCO.2015.63.6563","article-title":"Does valproic acid or levetiracetam improve survival in glioblastoma? A pooled analysis of prospective clinical trials in newly diagnosed glioblastoma","volume":"34","author":"Happold","year":"2016","journal-title":"J Clin Oncol."},{"issue":"7","key":"2023011310284782100_CIT0045","doi-asserted-by":"crossref","first-page":"961","DOI":"10.1093\/neuonc\/not057","article-title":"Effect of valproic acid on seizure control and on survival in patients with glioblastoma multiforme","volume":"15","author":"Kerkhof","year":"2013","journal-title":"Neuro Oncol."},{"issue":"3","key":"2023011310284782100_CIT0046","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1007\/s11060-016-2191-0","article-title":"Does the choice of antiepileptic drug affect survival in glioblastoma patients?","volume":"129","author":"Knudsen-baas","year":"2016","journal-title":"J Neurooncol."},{"issue":"1","key":"2023011310284782100_CIT0047","first-page":"1","article-title":"The addition of valproic acid to concurrent radiation therapy and temozolomide improves patient outcome: a correlative analysis of RTOG 0525, SEER and a phase II NCI trial","volume":"5","author":"Krauze","year":"2020","journal-title":"Cancer Stud Ther."},{"issue":"28","key":"2023011310284782100_CIT0048","doi-asserted-by":"crossref","first-page":"e21147","DOI":"10.1097\/MD.0000000000021147","article-title":"Effect of valproic acid on overall survival in patients with high-grade gliomas undergoing temozolomide: a nationwide population-based cohort study in Taiwan","volume":"99","author":"Kuo","year":"2020","journal-title":"Medicine."},{"issue":"3","key":"2023011310284782100_CIT0049","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1007\/s11060-012-0836-1","article-title":"Impact of antiepileptic drugs on thrombocytopenia in glioblastoma patients treated with standard chemoradiotherapy","volume":"108","author":"Simo","year":"2012","journal-title":"J Neurooncol."},{"issue":"1","key":"2023011310284782100_CIT0050","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1007\/s00415-014-7552-z","article-title":"Haematological toxicity of valproic acid compared to levetiracetam in patients with glioblastoma multiforme undergoing concomitant radio-chemotherapy: a retrospective cohort study","volume":"262","author":"Tinchon","year":"2015","journal-title":"J Neurol."},{"issue":"1","key":"2023011310284782100_CIT0051","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1186\/s12885-021-07800-0","article-title":"Clinical features associated with the efficacy of chemotherapy in patients with glioblastoma (GBM): a surveillance, epidemiology, and end results (SEER) analysis","volume":"21","author":"Wen","year":"2021","journal-title":"BMC Cancer."},{"issue":"9","key":"2023011310284782100_CIT0052","doi-asserted-by":"crossref","first-page":"1391","DOI":"10.1517\/13543784.2012.694425","article-title":"Valproic acid for the treatment of malignant gliomas: review of the preclinical rationale and published clinical results","volume":"21","author":"Berendsen","year":"2012","journal-title":"Expert Opin Investig Drugs."},{"issue":"1","key":"2023011310284782100_CIT0053","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1016\/S0959-8049(97)00374-2","article-title":"Prevalence and prognostic significance of epilepsy in patients with gliomas","volume":"34","author":"Lote","year":"1998","journal-title":"Eur J Cancer."},{"issue":"7","key":"2023011310284782100_CIT0054","doi-asserted-by":"crossref","first-page":"751","DOI":"10.1634\/theoncologist.2014-0060","article-title":"Seizure prognosis in brain tumors: new insights and evidence-based management","volume":"19","author":"Vecht","year":"2014","journal-title":"Oncologist."},{"issue":"6","key":"2023011310284782100_CIT0055","doi-asserted-by":"crossref","first-page":"605","DOI":"10.1038\/bjc.2016.36","article-title":"Inhibition of histone deacetylases in cancer therapy: lessons from leukaemia","volume":"114","author":"Ceccacci","year":"2016","journal-title":"Br J Cancer."},{"issue":"10","key":"2023011310284782100_CIT0056","doi-asserted-by":"crossref","first-page":"a026831","DOI":"10.1101\/cshperspect.a026831","article-title":"HDACs and HDAC inhibitors in cancer development and therapy","volume":"6","author":"Li","year":"2016","journal-title":"Cold Spring Harb Perspect Med."},{"issue":"3","key":"2023011310284782100_CIT0057","doi-asserted-by":"crossref","first-page":"257","DOI":"10.5301\/tj.5000347","article-title":"HDAC inhibitors: a new radiosensitizer for non-small-cell lung cancer","volume":"101","author":"Zhu","year":"2015","journal-title":"Tumori."},{"key":"2023011310284782100_CIT0058","first-page":"51","article-title":"Chromatin modulation by histone deacetylase inhibitors: impact on cellular sensitivity to ionizing radiation","volume":"5","author":"Carrier","year":"2013","journal-title":"Mol Cell Pharmacol."},{"issue":"3","key":"2023011310284782100_CIT0059","doi-asserted-by":"crossref","first-page":"380","DOI":"10.1002\/ijc.20774","article-title":"Enhancement of in vitro and in vivo tumor cell radiosensitivity by valproic acid","volume":"114","author":"Camphausen","year":"2005","journal-title":"Int J Cancer."},{"issue":"17","key":"2023011310284782100_CIT0060","doi-asserted-by":"crossref","first-page":"5410","DOI":"10.1158\/1078-0432.CCR-08-0643","article-title":"Postradiation sensitization of the histone deacetylase inhibitor valproic acid","volume":"14","author":"Chinnaiyan","year":"2008","journal-title":"Clin Cancer Res."},{"issue":"3","key":"2023011310284782100_CIT0061","doi-asserted-by":"crossref","first-page":"527","DOI":"10.4143\/crt.2014.026","article-title":"In vitro and in vivo radiosensitizing effect of valproic acid on fractionated irradiation","volume":"47","author":"Chie","year":"2015","journal-title":"Cancer Res Treat."},{"issue":"33","key":"2023011310284782100_CIT0062","doi-asserted-by":"crossref","first-page":"35004","DOI":"10.18632\/oncotarget.5253","article-title":"Valproic acid enhances the efficacy of radiation therapy by protecting normal hippocampal neurons and sensitizing malignant glioblastoma cells","volume":"6","author":"Thotala","year":"2015","journal-title":"Oncotarget."},{"issue":"1","key":"2023011310284782100_CIT0063","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1007\/s11060-011-0725-z","article-title":"Valproic acid sensitizes human glioma cells for temozolomide and \u03b3-radiation","volume":"107","author":"Van Nifterik","year":"2012","journal-title":"J Neurooncol."},{"issue":"3","key":"2023011310284782100_CIT0064","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1007\/s00109-010-0707-1","article-title":"Enhancement of temozolomide-induced apoptosis by valproic acid in human glioma cell lines through redox regulation","volume":"89","author":"Chen","year":"2011","journal-title":"J Mol Med (Berl)."},{"issue":"2","key":"2023011310284782100_CIT0065","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1016\/j.canlet.2009.03.013","article-title":"Histone deacetylase inhibitors as antineoplastic agents","volume":"280","author":"Batty","year":"2009","journal-title":"Cancer Lett."},{"issue":"1","key":"2023011310284782100_CIT0066","doi-asserted-by":"crossref","first-page":"35","DOI":"10.21873\/anticanres.11286","article-title":"Histone deacetylase inhibitors: an attractive therapeutic strategy against breast cancer","volume":"37","author":"Damaskos","year":"2017","journal-title":"Anticancer Res."},{"key":"2023011310284782100_CIT0067","doi-asserted-by":"crossref","first-page":"646384","DOI":"10.3389\/fimmu.2021.646384","article-title":"Valproic acid-like compounds enhance and prolong the radiotherapy effect on breast cancer by activating and maintaining anti-tumor immune function","volume":"12","author":"Cai","year":"2021","journal-title":"Front Immunol."},{"issue":"1-2","key":"2023011310284782100_CIT0068","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1615\/CritRevOncog.2014012393","article-title":"Modulation of immune responses by histone deacetylase inhibitors","volume":"20","author":"Schotterl","year":"2015","journal-title":"Crit Rev Oncog."},{"issue":"4","key":"2023011310284782100_CIT0069","doi-asserted-by":"crossref","first-page":"394","DOI":"10.1515\/raon-2015-0041","article-title":"Long-term survival in glioblastoma: Methyl guanine methyltransferase (MGMT) promoter methylation as independent favourable prognostic factor","volume":"50","author":"Smrdel","year":"2016","journal-title":"Radiol Oncol."},{"issue":"32","key":"2023011310284782100_CIT0070","doi-asserted-by":"crossref","first-page":"4085","DOI":"10.1200\/JCO.2013.49.6968","article-title":"Dose-dense temozolomide for newly diagnosed glioblastoma: a randomized phase III clinical trial","volume":"31","author":"Gilbert","year":"2013","journal-title":"J Clin Oncol."},{"issue":"5","key":"2023011310284782100_CIT0071","doi-asserted-by":"crossref","first-page":"1027","DOI":"10.3390\/ijms18051027","article-title":"The effect of VPA on increasing radiosensitivity in osteosarcoma cells and primary-culture cells from chemical carcinogen-induced breast cancer in rats","volume":"18","author":"Liu","year":"2017","journal-title":"Int J Mol Sci ."},{"key":"2023011310284782100_CIT0072","doi-asserted-by":"crossref","first-page":"646256","DOI":"10.3389\/fonc.2021.646256","article-title":"The valproate mediates radio-bidirectional regulation through RFWD3-dependent ubiquitination on Rad51","volume":"11","author":"Liu","year":"2021","journal-title":"Front Oncol."},{"issue":"1","key":"2023011310284782100_CIT0073","first-page":"25","article-title":"Expressional changes after histone deacetylase inhibition by valproic acid in LNCaP human prostate cancer cells","volume":"24","author":"Thelen","year":"2004","journal-title":"Int J Oncol."},{"issue":"4","key":"2023011310284782100_CIT0074","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1179\/joc.2006.18.4.415","article-title":"Synergistic effects of valproic acid and mitomycin C in adenocarcinoma cell lines and fresh tumor cells of patients with colon cancer","volume":"18","author":"Friedmann","year":"2006","journal-title":"J Chemother."},{"issue":"4","key":"2023011310284782100_CIT0075","first-page":"386","article-title":"Epigenetic therapy and cisplatin chemoradiation in FIGO stage IIIB cervical cancer","volume":"31","author":"Candelaria","year":"2010","journal-title":"Eur J Gynaecol Oncol."},{"key":"2023011310284782100_CIT0076","first-page":"1155","article-title":"Valproic acid combined with cisplatin-based chemoradiation in locally advanced head and neck squamous cell carcinoma patients and associated biomarkers","volume":"14","author":"Mak","year":"2020","journal-title":"Ecancermedicalscience."},{"issue":"2","key":"2023011310284782100_CIT0077","doi-asserted-by":"crossref","first-page":"308","DOI":"10.1016\/j.radonc.2015.10.009","article-title":"Antiepileptic drug use improves overall survival in breast cancer patients with brain metastases in the setting of whole brain radiotherapy","volume":"117","author":"Reddy","year":"2015","journal-title":"Radiother Oncol."},{"issue":"1","key":"2023011310284782100_CIT0078","doi-asserted-by":"crossref","first-page":"875","DOI":"10.1186\/1471-2407-14-875","article-title":"Phase 1\/2 study of valproic acid and short-course radiotherapy plus capecitabine as preoperative treatment in low-moderate risk rectal cancer-V-shoRT-R3 (Valproic acid-short Radiotherapy-rectum 3rd trial)","volume":"14","author":"Avallone","year":"2014","journal-title":"BMC Cancer."},{"key":"2023011310284782100_CIT0079","author":"European Medicines Agency - Farydak (panobinostat).","year":"2015"},{"issue":"7","key":"2023011310284782100_CIT0080","doi-asserted-by":"crossref","first-page":"1414","DOI":"10.3390\/ijms18071414","article-title":"Histone deacetylase inhibitors as anticancer drugs","volume":"18","author":"Eckschlager","year":"2017","journal-title":"Int J Mol Sci ."},{"issue":"4","key":"2023011310284782100_CIT0081","doi-asserted-by":"crossref","first-page":"546","DOI":"10.1093\/neuonc\/nox161","article-title":"Phase I\/II trial of vorinostat combined with temozolomide and radiation therapy for newly diagnosed glioblastoma: results of Alliance N0874\/ABTC 02","volume":"20","author":"Galanis","year":"2018","journal-title":"Neuro Oncol."},{"key":"2023011310284782100_CIT0082","doi-asserted-by":"crossref","first-page":"vi2","DOI":"10.1093\/neuonc\/noy148.005","article-title":"ATIM-08. A phase I trial of pembrolizumab and vorinostat combined with temozolomide and radiation therapy for newly diagnosed glioblastoma (NCT03426891)","volume":"20","author":"Sahebjam","year":"2018","journal-title":"Neuro Oncol."},{"issue":"4","key":"2023011310284782100_CIT0083","doi-asserted-by":"crossref","first-page":"702","DOI":"10.1007\/s10637-018-0696-4","article-title":"A phase 1 trial of vorinostat in combination with concurrent chemoradiation therapy in the treatment of advanced staged head and neck squamous cell carcinoma","volume":"37","author":"Teknos","year":"2019","journal-title":"Invest New Drugs."},{"issue":"3","key":"2023011310284782100_CIT0084","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1007\/s11060-016-2059-3","article-title":"Phase I trial of panobinostat and fractionated stereotactic re-irradiation therapy for recurrent high grade gliomas","volume":"127","author":"Shi","year":"2016","journal-title":"J Neuro Oncol."},{"issue":"15","key":"2023011310284782100_CIT0085","doi-asserted-by":"crossref","first-page":"7553","DOI":"10.1200\/jco.2015.33.15_suppl.7553","article-title":"Phase I study of vorinostat with concurrent chemoradiotherapy (CRT) for locally advanced non-squamous non-small cell lung cancer (NSCLC)","volume":"33","author":"Mehra","year":"2015","journal-title":"J Clin Oncol."},{"issue":"3","key":"2023011310284782100_CIT0086","doi-asserted-by":"crossref","first-page":"S109","DOI":"10.1016\/j.ijrobp.2015.07.262","article-title":"Phase 2, open-label, trial evaluating safety, tolerability, and preliminary antitumor activity of panobinostat and fractionated stereotactic reirradiation therapy for recurrent high-grade gliomas","volume":"93","author":"Palmer","year":"2015","journal-title":"Int J Radiat Oncol Biol Phys."},{"issue":"10","key":"2023011310284782100_CIT0087","doi-asserted-by":"crossref","first-page":"926","DOI":"10.2174\/1570159X17666181227165722","article-title":"Valproic acid and epilepsy: from molecular mechanisms to clinical evidences","volume":"17","author":"Romoli","year":"2019","journal-title":"Curr Neuropharmacol."},{"issue":"1","key":"2023011310284782100_CIT0088","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1111\/j.1528-1167.2011.03316.x","article-title":"Effects of long-term antiepileptic drug monotherapy on vascular risk factors and atherosclerosis","volume":"53","author":"Chuang","year":"2012","journal-title":"Epilepsia."},{"issue":"9","key":"2023011310284782100_CIT0089","doi-asserted-by":"crossref","first-page":"677","DOI":"10.1016\/j.seizure.2014.05.011","article-title":"The effects of antiepileptic drugs on vascular risk factors: a narrative review","volume":"23","author":"Katsiki","year":"2014","journal-title":"Seizure."},{"issue":"1","key":"2023011310284782100_CIT0090","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1215\/15228517-2006-024","article-title":"The impact of thrombocytopenia from temozolomide and radiation in newly diagnosed adults with high-grade gliomas","volume":"9","author":"Gerber","year":"2007","journal-title":"Neuro Oncol."},{"issue":"9","key":"2023011310284782100_CIT0091","doi-asserted-by":"crossref","first-page":"688","DOI":"10.1212\/01.wnl.0000255937.27012.ee","article-title":"Safety and feasibility of long-term temozolomide treatment in patients with high-grade glioma","volume":"68","author":"Hau","year":"2007","journal-title":"Neurology."},{"issue":"1","key":"2023011310284782100_CIT0092","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1007\/s00280-011-1679-8","article-title":"Hematologic adverse events associated with temozolomide","volume":"69","author":"Villano","year":"2012","journal-title":"Cancer Chemother Pharmacol."},{"issue":"3","key":"2023011310284782100_CIT0093","doi-asserted-by":"crossref","first-page":"288","DOI":"10.4161\/cc.5.3.2421","article-title":"The paradox of histone deacetylase inhibitor-mediated modulation of cellular responses to radiation","volume":"5","author":"Karagiannis","year":"2006","journal-title":"Cell Cycle."},{"issue":"1","key":"2023011310284782100_CIT0094","doi-asserted-by":"crossref","first-page":"697","DOI":"10.1016\/j.ijrobp.2008.06.600","article-title":"Valproic acid shows normal tissue protection in a rat spinal cord model","volume":"72","author":"Kornguth","year":"2008","journal-title":"Int J Radiat Oncol Biol Phys."},{"issue":"11","key":"2023011310284782100_CIT0095","doi-asserted-by":"crossref","first-page":"1199","DOI":"10.1080\/13543784.2017.1386172","article-title":"Targeting triple-negative breast cancer with histone deacetylase inhibitors","volume":"26","author":"Fedele","year":"2017","journal-title":"Expert Opin Investig Drugs."},{"issue":"1","key":"2023011310284782100_CIT0096","doi-asserted-by":"crossref","first-page":"63","DOI":"10.3892\/br.2014.367","article-title":"Radioprotective effects of valproic acid, a histone deacetylase inhibitor, in the rat brain","volume":"3","author":"Zhou","year":"2015","journal-title":"Biomed Rep."},{"issue":"4","key":"2023011310284782100_CIT0097","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1007\/s00411-011-0384-7","article-title":"Radioprotection by the histone deacetylase inhibitor phenylbutyrate","volume":"50","author":"Miller","year":"2011","journal-title":"Radiat Environ Biophys."},{"issue":"6","key":"2023011310284782100_CIT0098","doi-asserted-by":"crossref","first-page":"779","DOI":"10.1093\/neuonc\/nov269","article-title":"Epilepsy in glioma patients: mechanisms, management, and impact of anticonvulsant therapy","volume":"18","author":"Armstrong","year":"2015","journal-title":"Neuro Oncol."}],"container-title":["Neuro-Oncology Practice"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/nop\/advance-article-pdf\/doi\/10.1093\/nop\/npac078\/46673659\/npac078.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/nop\/article-pdf\/10\/1\/13\/48626056\/npac078.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/nop\/article-pdf\/10\/1\/13\/48626056\/npac078.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,1,13]],"date-time":"2023-01-13T20:41:50Z","timestamp":1673642510000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/nop\/article\/10\/1\/13\/6732510"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,9,30]]},"references-count":98,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2022,9,30]]},"published-print":{"date-parts":[[2023,1,13]]}},"URL":"https:\/\/doi.org\/10.1093\/nop\/npac078","relation":{},"ISSN":["2054-2577","2054-2585"],"issn-type":[{"value":"2054-2577","type":"print"},{"value":"2054-2585","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2023,2,1]]},"published":{"date-parts":[[2022,9,30]]}}}